Disease · MONDO_0005461

endometrium adenocarcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. endometrium adenocarcinoma. Diseases, record MONDO_0005461. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005461

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: endometrium adenocarcinoma; Open Targets
Open Targets ID: MONDO_0005461; Open Targets
Other names: adenocarcinoma of endometrium, adenocarcinoma of the endometrium, adenocarcinoma of uterus, adenocarcinoma, endometrial, malignant, endometrial adenoacanthoma, endometrial adenocarcinoma, endometrial endometrioid adenocarcinoma with squamous differentiation, endometrioid adenoma or carcinoma, endometrioid adenoma or carcinoma NOS (morphologic abnormality), endometrioid adenomas and carcinomas, endometrioid adenomas and carcinomas (morphologic abnormality), endometrioid carcinoma of endometrium; Open Targets
Disease Ontology: DOID:2870; Disease Ontology
NCI Thesaurus: C7359; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 1 of its 20 drugs, from ClinicalTrials.gov; Open Targets

Drugs20

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ESTROGENS, CONJUGATED	CHEMBL1201649		Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
METFORMIN	CHEMBL1431	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
MEDROXYPROGESTERONE ACETATE	CHEMBL717	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
MEGESTROL ACETATE	CHEMBL1201139	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ABEMACICLIB	CHEMBL3301610	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
AMIFOSTINE	CHEMBL1006	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ARSENIC TRIOXIDE	CHEMBL5483015	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CYANOCOBALAMIN	CHEMBL2110563	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 20

See all 20 drugs

Targets93

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PGR	Progesterone receptor	3	Progesterone receptor agonist	Phase 2	https://conductscience.org/library/genes/5241	Drugs and targets
ESR1	Estrogen receptor	2	Estrogen receptor agonist; Estrogen receptor alpha antagonist; Estrogen receptor degrader	Phase 3	https://conductscience.org/library/genes/2099	Drugs and targets
TUBA1A	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/81027	Drugs and targets

1 to 10 of 93

See all 93 targets

Trials17

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01968317	Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma	Phase 2	150	2021-09-13	Endometrial Atypical Hyperplasia, Endometrial Adenocarcinoma	MEGESTROL ACETATE, METFORMIN	Its record names the disease	ClinicalTrials.gov
NCT00095979	Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer	Phase 2	52	2015-05-21	Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Stage IV Endometrial Carcinoma	IXABEPILONE	Its record names the disease	ClinicalTrials.gov
NCT02549209	Pembro/Carbo/Taxol in Endometrial Cancer	Phase 2	46	2021-11-30	Endometrial Cancer, Endometrial Adenocarcinoma	CARBOPLATIN, PACLITAXEL, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00584857	A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer	Phase 2	30	2012-03-29	Uterine Cancer	CARBOPLATIN, MEGESTROL ACETATE, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT00820898	Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer	Phase 2	24	2017-12-05	Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Recurrent Uterine Corpus Carcinoma	GEMCITABINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT02035787	Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients	Phase 2	20	2024-12-18	Complex Atypical Hyperplasia, Endometrial Cancer	METFORMIN	Its record names the disease	ClinicalTrials.gov
NCT00584909	A Phase II Study of Paclitaxel and Carboplatin in Patients With an Elevated-Risk Cancer of the Uterus	Phase 2	13	2012-03-29	Uterine Cancer	CARBOPLATIN, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT01184053	Trisenox® in Women With Metastatic Endometrial Cancer	Phase 2	3	2017-06-14	Endometrial Carcinoma	ARSENIC TRIOXIDE	Its record names the disease	ClinicalTrials.gov
NCT00002976	Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer	Phase 3	2,108		Endometrial Cancer	ESTROGENS, CONJUGATED	Its record names the disease	ClinicalTrials.gov
NCT01686126	Improving the Treatment for Women With Early Stage Cancer of the Uterus	Phase 2	165		Complex Endometrial Hyperplasia With Atypia, Grade 1 Endometrial Endometrioid Adenocarcinoma	LEVONORGESTREL, METFORMIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 17

See all 17 trials

Comparisons in its trials9

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Megestrol Acetate and Metformin vs Megestrol Acetate: deaths from any cause	0 of 76	0 of 74	150	NCT01968317	Trial comparisons
Megestrol Acetate and Metformin vs Megestrol Acetate: serious adverse events	0 of 76	0 of 74	150	NCT01968317	Trial comparisons
Megestrol Acetate and Metformin vs Megestrol Acetate: Cumulative CR Rates Within 32 Weeks	52 of 70	45 of 66	136	NCT01968317	Trial comparisons
Megestrol Acetate and Metformin vs Megestrol Acetate: Recurrence Rate	7 of 69	6 of 66	135	NCT01968317	Trial comparisons
Megestrol Acetate and Metformin vs Megestrol Acetate: Cumulative CR Rates Within 16 Weeks	23 of 67	12 of 58	125	NCT01968317	Trial comparisons
Megestrol Acetate and Metformin vs Megestrol Acetate: Pregnancy Rate	19 of 37	15 of 31	68	NCT01968317	Trial comparisons
Complex Atypical Hyperplasia vs Grade 1 Endometrial Adenocarcinoma: deaths from any cause	0 of 12	0 of 8	20	NCT02035787	Trial comparisons
Complex Atypical Hyperplasia vs Grade 1 Endometrial Adenocarcinoma: serious adverse events	0 of 12	1 of 8	20	NCT02035787	Trial comparisons
Complex Atypical Hyperplasia vs Grade 1 Endometrial Adenocarcinoma: Adherence of Treatment	10 of 11	7 of 7	18	NCT02035787	Trial comparisons

Papers from its trials7

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
24724218	RESULT	1	PubMed
19804902	RESULT	1	PubMed
16446331	RESULT	1	PubMed
15721401	RESULT	1	PubMed
41286566	DERIVED	1	PubMed
35551299	DERIVED	1	PubMed
33762086	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005461

GET https://conductscience.org/api/diseases/v1/MONDO_0005461/targets?page=2

API reference For AI assistants